Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · IEX Real-Time Price · USD
65.35
+1.01 (1.57%)
May 3, 2024, 12:58 PM EDT - Market open
Cytokinetics Revenue
In the year 2023, Cytokinetics had annual revenue of $7.53M, a decrease of -92.04%. Revenue in the quarter ending December 31, 2023 was $1.67M, a -14.56% decrease year-over-year.
Revenue (ttm)
$7.53M
Revenue Growth
-92.04%
P/S Ratio
910.63
Revenue / Employee
$17,801
Employees
423
Market Cap
6.85B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
Dec 31, 2019 | 26.87M | -4.63M | -14.71% |
Dec 31, 2018 | 31.50M | 18.13M | 135.64% |
Dec 31, 2017 | 13.37M | -93.04M | -87.44% |
Dec 31, 2016 | 106.41M | 77.75M | 271.30% |
Dec 31, 2015 | 28.66M | -18.28M | -38.95% |
Dec 31, 2014 | 46.94M | 16.29M | 53.16% |
Dec 31, 2013 | 30.65M | 23.09M | 305.45% |
Dec 31, 2012 | 7.56M | 3.56M | 88.98% |
Dec 31, 2011 | 4.00M | 1.42M | 55.22% |
Dec 31, 2010 | 2.58M | -78.96M | -96.84% |
Dec 31, 2009 | 81.54M | 69.12M | 556.51% |
Dec 31, 2008 | 12.42M | -1.20M | -8.82% |
Dec 31, 2007 | 13.62M | 10.50M | 335.63% |
Dec 31, 2006 | 3.13M | -5.79M | -64.91% |
Dec 31, 2005 | 8.91M | -4.53M | -33.70% |
Dec 31, 2004 | 13.44M | 2.87M | 27.09% |
Dec 31, 2003 | 10.58M | -819.00K | -7.19% |
Dec 31, 2002 | 11.40M | 2.93M | 34.61% |
Dec 31, 2001 | 8.47M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elanco Animal Health | 4.42B |
DENTSPLY SIRONA | 3.97B |
The Ensign Group | 3.73B |
Globus Medical | 1.57B |
HealthEquity | 999.59M |
Ionis Pharmaceuticals | 787.65M |
Blueprint Medicines | 249.38M |
Revolution Medicines | 11.58M |
CYTK News
- 21 hours ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress - GlobeNewsWire
- 8 days ago - Cytokinetics to Announce First Quarter Results on May 8, 2024 - GlobeNewsWire
- 23 days ago - This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? - Market Watch
- 23 days ago - Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress - GlobeNewsWire
- 4 weeks ago - Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session - GlobeNewsWire
- 4 weeks ago - Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session - GlobeNewsWire